Results 121 to 130 of about 81,528 (247)

Unveiling Rare Genetic Variants in DAB2IP: New Insights Into the Pathogenesis of Recurrent Angioedema

open access: yes
Allergy, EarlyView.
Maurizio Margaglione   +8 more
wiley   +1 more source

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report

open access: yesAllergy, EarlyView.
ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T‐helper cell 2 (T2)‐high inflammation, driven by interleukin (IL)‐4, IL‐5, and IL‐13 cytokines.
Sanna Toppila‐Salmi   +21 more
wiley   +1 more source

Vitamin D Deficiency in Chronic Idiopathic Urticaria

open access: yesIranian Journal of Allergy, Asthma and Immunology, 2015
Chronic urticaria is the most common skin diseases, characterized by chronic cutaneous lesions which severely debilitates patients in several aspects of their everyday life.
Masoud Movahedi   +10 more
doaj  

What′s new in urticaria ?

open access: yesIndian Journal of Dermatology, 2009
Urticaria, a perplexing disease of ever-changing explanations, is being renovated almost everyday by newer facts and findings accumulated from different parts of the globe.
Ghosh Sanjay
doaj  

A One‐Strength Dose Escalation Regimen for Birch Pollen SCIT Is Safe and Tolerable in Children, Adolescents, and Adults

open access: yesAllergy, EarlyView.
This study evaluated safety and tolerability of birch pollen SCIT during dose escalation with a new One‐Strength regimen (3 injections, Strength B) compared to the Standard regimen (7 injections, Strengths A and B) in patients aged 5–65 years. Safety and tolerability were comparable between the two regimens in adults, adolescents, and adolescents, as ...
Marek Jutel   +5 more
wiley   +1 more source

Successful Application of the Mast Cell Activation Test in Immediate Hypersensitivity to Amoxicillin

open access: yesAllergy, EarlyView.
This study included 28 amoxicillin‐allergic patients and 11 healthy exposed controls. Mast cells were differentiated from CD34+ progenitors over 8 weeks using cytokine cocktails. The mast cell activation test involved sensitization with patient or control sera and stimulation with free amoxicillin or G4/G5‐AXO dendrimers with successfully activated ...
Jose A. Céspedes   +11 more
wiley   +1 more source

Codfish Oral Immunotherapy in Children Aged 2–10: Randomized Placebo‐Controlled Study

open access: yesAllergy, EarlyView.
Codfish OIT significantly increased desensitization in children with fish allergy (43% vs. 11% placebo, p = 0.003), with 69% achieving 10‐fold threshold increases versus 26% in placebo (p = 0.0003). Sustained unresponsiveness remained limited (23% vs. 9%, p = 0.332). Treatment demonstrated acceptable safety with predominantly mild reactions and reduced
Agnes Sze‐yin Leung   +9 more
wiley   +1 more source

Effect of Intramuscular Adrenaline on Histamine‐Induced Hypotension: A Randomised Placebo‐Controlled Pilot Trial

open access: yesAllergy, EarlyView.
Histamine infusions induce reproducible severe hypotension. Intramuscular adrenaline showed ‘supposedly therapeutic’ plasma concentrations but did not produce a sustained clinically relevant improvement in shock in the majority of recipients. These findings question adrenaline pharmacokinetic surrogate thresholds and support the need for faster and ...
Matthias Weiss‐Tessbach   +12 more
wiley   +1 more source

Murine Model of Chronic Spontaneous Urticaria‐Like Skin

open access: yes
Allergy, EarlyView.
Yanan He   +4 more
wiley   +1 more source

A Case for Anti‐IgE Vaccination

open access: yesAllergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy